Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
<p><strong>Introduction:</strong> The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inh...
Main Authors: | Tarrant, J, Galien, R, Li, W, Goyal, L, Pan, Y, Hawtin, R, Zhang, W, Van Der Aa, A, Taylor, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Verlag
2020
|
Similar Items
-
The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018) -
Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018) -
Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019) -
Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017) -
Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)